Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study

Imo A. Ebong, Karol E. Watson, Kristen G. Hairston, Mercedes R. Carnethon, Pamela Ouyang, Moyses Szklo, Alain G. Bertoni

Research output: Contribution to journalArticle

Abstract

Objectives We investigated the association between menopausal hormone therapy (MHT) and incident type 2 diabetes in postmenopausal women, and explored the potential modifying role of body fat distribution on this association. Methods We included 2210 postmenopausal women without prevalent diabetes at recruitment (2000–2002) from the Multiethnic Study of Atherosclerosis. Cox proportional hazards models were used to examine associations of MHT and MHT types with incident diabetes, testing for variation according to body fat distribution. Results Over a median follow-up of 11.1 years, there were 226 incident cases of diabetes. There were no significant interactions with central or generalized body fatness. In fully adjusted models, current and past MHT use was associated with a greater risk of incident diabetes [HR: 1.66 (1.18–2.35) and 1.60 (1.11–2.30) respectively]. Estrogen only (ET) and combined progestin and estrogen (PET) formulations were similarly associated with a greater risk of incident diabetes [HR: 1.52 (1.03–2.24) and 1.77 (1.15–2.72) respectively]. Conclusions In our observational study of middle-aged and older, non-diabetic postmenopausal women, a current or past use of MHT was independently associated with a greater risk of incident diabetes. ET and PET are associated with similar risks of incident diabetes in postmenopausal women. The association of MHT use with incident diabetes is the same irrespective of body mass index (BMI) or waist circumference.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalMaturitas
Volume91
DOIs
StatePublished - Sep 1 2016

Fingerprint

Body Fat Distribution
Medical problems
Type 2 Diabetes Mellitus
Fats
Hormones
Estrogens
Progestins
Therapeutics
Waist Circumference
Proportional Hazards Models
Observational Studies
Atherosclerosis
Body Mass Index
Hazards

Keywords

  • Body fat
  • Diabetes
  • Menopausal hormone therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study. / Ebong, Imo A.; Watson, Karol E.; Hairston, Kristen G.; Carnethon, Mercedes R.; Ouyang, Pamela; Szklo, Moyses; Bertoni, Alain G.

In: Maturitas, Vol. 91, 01.09.2016, p. 147-152.

Research output: Contribution to journalArticle

Ebong, Imo A. ; Watson, Karol E. ; Hairston, Kristen G. ; Carnethon, Mercedes R. ; Ouyang, Pamela ; Szklo, Moyses ; Bertoni, Alain G. / Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study. In: Maturitas. 2016 ; Vol. 91. pp. 147-152.
@article{967d4d1e464241aa81bb807dc4204ac8,
title = "Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study",
abstract = "Objectives We investigated the association between menopausal hormone therapy (MHT) and incident type 2 diabetes in postmenopausal women, and explored the potential modifying role of body fat distribution on this association. Methods We included 2210 postmenopausal women without prevalent diabetes at recruitment (2000–2002) from the Multiethnic Study of Atherosclerosis. Cox proportional hazards models were used to examine associations of MHT and MHT types with incident diabetes, testing for variation according to body fat distribution. Results Over a median follow-up of 11.1 years, there were 226 incident cases of diabetes. There were no significant interactions with central or generalized body fatness. In fully adjusted models, current and past MHT use was associated with a greater risk of incident diabetes [HR: 1.66 (1.18–2.35) and 1.60 (1.11–2.30) respectively]. Estrogen only (ET) and combined progestin and estrogen (PET) formulations were similarly associated with a greater risk of incident diabetes [HR: 1.52 (1.03–2.24) and 1.77 (1.15–2.72) respectively]. Conclusions In our observational study of middle-aged and older, non-diabetic postmenopausal women, a current or past use of MHT was independently associated with a greater risk of incident diabetes. ET and PET are associated with similar risks of incident diabetes in postmenopausal women. The association of MHT use with incident diabetes is the same irrespective of body mass index (BMI) or waist circumference.",
keywords = "Body fat, Diabetes, Menopausal hormone therapy",
author = "Ebong, {Imo A.} and Watson, {Karol E.} and Hairston, {Kristen G.} and Carnethon, {Mercedes R.} and Pamela Ouyang and Moyses Szklo and Bertoni, {Alain G.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.maturitas.2016.06.020",
language = "English (US)",
volume = "91",
pages = "147--152",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study

AU - Ebong, Imo A.

AU - Watson, Karol E.

AU - Hairston, Kristen G.

AU - Carnethon, Mercedes R.

AU - Ouyang, Pamela

AU - Szklo, Moyses

AU - Bertoni, Alain G.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objectives We investigated the association between menopausal hormone therapy (MHT) and incident type 2 diabetes in postmenopausal women, and explored the potential modifying role of body fat distribution on this association. Methods We included 2210 postmenopausal women without prevalent diabetes at recruitment (2000–2002) from the Multiethnic Study of Atherosclerosis. Cox proportional hazards models were used to examine associations of MHT and MHT types with incident diabetes, testing for variation according to body fat distribution. Results Over a median follow-up of 11.1 years, there were 226 incident cases of diabetes. There were no significant interactions with central or generalized body fatness. In fully adjusted models, current and past MHT use was associated with a greater risk of incident diabetes [HR: 1.66 (1.18–2.35) and 1.60 (1.11–2.30) respectively]. Estrogen only (ET) and combined progestin and estrogen (PET) formulations were similarly associated with a greater risk of incident diabetes [HR: 1.52 (1.03–2.24) and 1.77 (1.15–2.72) respectively]. Conclusions In our observational study of middle-aged and older, non-diabetic postmenopausal women, a current or past use of MHT was independently associated with a greater risk of incident diabetes. ET and PET are associated with similar risks of incident diabetes in postmenopausal women. The association of MHT use with incident diabetes is the same irrespective of body mass index (BMI) or waist circumference.

AB - Objectives We investigated the association between menopausal hormone therapy (MHT) and incident type 2 diabetes in postmenopausal women, and explored the potential modifying role of body fat distribution on this association. Methods We included 2210 postmenopausal women without prevalent diabetes at recruitment (2000–2002) from the Multiethnic Study of Atherosclerosis. Cox proportional hazards models were used to examine associations of MHT and MHT types with incident diabetes, testing for variation according to body fat distribution. Results Over a median follow-up of 11.1 years, there were 226 incident cases of diabetes. There were no significant interactions with central or generalized body fatness. In fully adjusted models, current and past MHT use was associated with a greater risk of incident diabetes [HR: 1.66 (1.18–2.35) and 1.60 (1.11–2.30) respectively]. Estrogen only (ET) and combined progestin and estrogen (PET) formulations were similarly associated with a greater risk of incident diabetes [HR: 1.52 (1.03–2.24) and 1.77 (1.15–2.72) respectively]. Conclusions In our observational study of middle-aged and older, non-diabetic postmenopausal women, a current or past use of MHT was independently associated with a greater risk of incident diabetes. ET and PET are associated with similar risks of incident diabetes in postmenopausal women. The association of MHT use with incident diabetes is the same irrespective of body mass index (BMI) or waist circumference.

KW - Body fat

KW - Diabetes

KW - Menopausal hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=84978870795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978870795&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2016.06.020

DO - 10.1016/j.maturitas.2016.06.020

M3 - Article

VL - 91

SP - 147

EP - 152

JO - Maturitas

JF - Maturitas

SN - 0378-5122

ER -